1.Trends of Syphilis in a Single Tertiary Center:A 24-Year Demographic, Clinical, and Serologic Analysis
Dong Il JEONG ; Sang Yeop PARK ; Tae Wook KIM ; Moojung KIM ; Sanghyun PARK ; Hee Joo KIM ; Jin Ok BAEK
Korean Journal of Dermatology 2025;63(2):29-39
Background:
Syphilis, an infectious and chronic disease primarily transmitted through sexual contact, is caused by the spirochete bacterium Treponema pallidum. Although the introduction of penicillin has significantly reduced its incidence, syphilis continues to have a substantial impact on public health.
Objective:
The purpose of this study was to investigate trends in syphilis and to analyze its epidemiologic, clinical, and serologic characteristics.
Methods:
We retrospectively reviewed the medical records of 330 patients who tested positive for the Venereal Disease Research Laboratory (VDRL) test, including 192 patients who received a diagnosis of syphilis and who visited the Dermatology Department of Gachon University Gil Medical Center between 2000 and 2023. Statistical analyses were performed to evaluate trends in syphilis incidence and related variable factors, such as sex, age, and serological results.
Results:
The average age of the 192 syphilis patients was 34.18±15.81 years, with a male-to-female ratio of 1:1.2. The most prevalent age group was 20∼29 years, comprising 71 patients (37.0%). Over time, the incidence of syphilis demonstrated a decreasing trend (p<0.001). A total of 105 patients (54.7%) were diagnosed with symptomatic syphilis, with a male-to-female ratio of 1.5:1. The proportion of symptomatic syphilis patients tended to decrease with increasing age (p<0.05). Maculopapular syphilis was the most frequently observed presentation in secondary syphilis (36.2%). The proportion of symptomatic syphilis patients significantly increased with higher VDRL titers (p<0.001).
Conclusion
The incidence of syphilis has shown a consistent decline over the past two decades. However, the relatively higher prevalence among younger age groups indicates the need for continued public health efforts.
2.Regorafenib-Induced Hand-Foot Skin Reaction and Scrotal Dermatitis in a Patient with Hepatocellular Carcinoma
Dong Il JEONG ; Sang Yeop PARK ; Tae Wook KIM ; Moojung KIM ; Jin Ok BAEK
Korean Journal of Dermatology 2025;63(2):56-60
Regorafenib is an oral multikinase inhibitor used to treat advanced solid tumors, including hepatocellular carcinoma (HCC), gastrointestinal stromal tumors, and colorectal cancer. Adverse dermatological reactions are common after regorafenib treatment. The most frequent cutaneous adverse reaction is hand-foot skin reaction (HFSR). Compared to HFSR, reports on adverse reactions on the scrotum associated with regorafenib are limited. Only a few cases of adverse reactions on the scrotum associated with HFSR have been reported. We present the case of a 55-year-old male patient with a 1-year history of scrotal dermatitis and HFSR, who had been undergoing treatment for HCC.One year after administration of oral regorafenib (160 mg/d), multiple vesicles, pustules, desquamation, and hyperkeratosis developed on both hands and feet, accompanied by scaly erythematous plaques around the scrotum.The lesions improved after two weeks of treatment with topical and systemic steroids. Herein, we report a rare case of scrotal dermatitis associated with regorafenib-induced HFSR.
3.Trends of Syphilis in a Single Tertiary Center:A 24-Year Demographic, Clinical, and Serologic Analysis
Dong Il JEONG ; Sang Yeop PARK ; Tae Wook KIM ; Moojung KIM ; Sanghyun PARK ; Hee Joo KIM ; Jin Ok BAEK
Korean Journal of Dermatology 2025;63(2):29-39
Background:
Syphilis, an infectious and chronic disease primarily transmitted through sexual contact, is caused by the spirochete bacterium Treponema pallidum. Although the introduction of penicillin has significantly reduced its incidence, syphilis continues to have a substantial impact on public health.
Objective:
The purpose of this study was to investigate trends in syphilis and to analyze its epidemiologic, clinical, and serologic characteristics.
Methods:
We retrospectively reviewed the medical records of 330 patients who tested positive for the Venereal Disease Research Laboratory (VDRL) test, including 192 patients who received a diagnosis of syphilis and who visited the Dermatology Department of Gachon University Gil Medical Center between 2000 and 2023. Statistical analyses were performed to evaluate trends in syphilis incidence and related variable factors, such as sex, age, and serological results.
Results:
The average age of the 192 syphilis patients was 34.18±15.81 years, with a male-to-female ratio of 1:1.2. The most prevalent age group was 20∼29 years, comprising 71 patients (37.0%). Over time, the incidence of syphilis demonstrated a decreasing trend (p<0.001). A total of 105 patients (54.7%) were diagnosed with symptomatic syphilis, with a male-to-female ratio of 1.5:1. The proportion of symptomatic syphilis patients tended to decrease with increasing age (p<0.05). Maculopapular syphilis was the most frequently observed presentation in secondary syphilis (36.2%). The proportion of symptomatic syphilis patients significantly increased with higher VDRL titers (p<0.001).
Conclusion
The incidence of syphilis has shown a consistent decline over the past two decades. However, the relatively higher prevalence among younger age groups indicates the need for continued public health efforts.
4.Regorafenib-Induced Hand-Foot Skin Reaction and Scrotal Dermatitis in a Patient with Hepatocellular Carcinoma
Dong Il JEONG ; Sang Yeop PARK ; Tae Wook KIM ; Moojung KIM ; Jin Ok BAEK
Korean Journal of Dermatology 2025;63(2):56-60
Regorafenib is an oral multikinase inhibitor used to treat advanced solid tumors, including hepatocellular carcinoma (HCC), gastrointestinal stromal tumors, and colorectal cancer. Adverse dermatological reactions are common after regorafenib treatment. The most frequent cutaneous adverse reaction is hand-foot skin reaction (HFSR). Compared to HFSR, reports on adverse reactions on the scrotum associated with regorafenib are limited. Only a few cases of adverse reactions on the scrotum associated with HFSR have been reported. We present the case of a 55-year-old male patient with a 1-year history of scrotal dermatitis and HFSR, who had been undergoing treatment for HCC.One year after administration of oral regorafenib (160 mg/d), multiple vesicles, pustules, desquamation, and hyperkeratosis developed on both hands and feet, accompanied by scaly erythematous plaques around the scrotum.The lesions improved after two weeks of treatment with topical and systemic steroids. Herein, we report a rare case of scrotal dermatitis associated with regorafenib-induced HFSR.
5.Trends of Syphilis in a Single Tertiary Center:A 24-Year Demographic, Clinical, and Serologic Analysis
Dong Il JEONG ; Sang Yeop PARK ; Tae Wook KIM ; Moojung KIM ; Sanghyun PARK ; Hee Joo KIM ; Jin Ok BAEK
Korean Journal of Dermatology 2025;63(2):29-39
Background:
Syphilis, an infectious and chronic disease primarily transmitted through sexual contact, is caused by the spirochete bacterium Treponema pallidum. Although the introduction of penicillin has significantly reduced its incidence, syphilis continues to have a substantial impact on public health.
Objective:
The purpose of this study was to investigate trends in syphilis and to analyze its epidemiologic, clinical, and serologic characteristics.
Methods:
We retrospectively reviewed the medical records of 330 patients who tested positive for the Venereal Disease Research Laboratory (VDRL) test, including 192 patients who received a diagnosis of syphilis and who visited the Dermatology Department of Gachon University Gil Medical Center between 2000 and 2023. Statistical analyses were performed to evaluate trends in syphilis incidence and related variable factors, such as sex, age, and serological results.
Results:
The average age of the 192 syphilis patients was 34.18±15.81 years, with a male-to-female ratio of 1:1.2. The most prevalent age group was 20∼29 years, comprising 71 patients (37.0%). Over time, the incidence of syphilis demonstrated a decreasing trend (p<0.001). A total of 105 patients (54.7%) were diagnosed with symptomatic syphilis, with a male-to-female ratio of 1.5:1. The proportion of symptomatic syphilis patients tended to decrease with increasing age (p<0.05). Maculopapular syphilis was the most frequently observed presentation in secondary syphilis (36.2%). The proportion of symptomatic syphilis patients significantly increased with higher VDRL titers (p<0.001).
Conclusion
The incidence of syphilis has shown a consistent decline over the past two decades. However, the relatively higher prevalence among younger age groups indicates the need for continued public health efforts.
6.Regorafenib-Induced Hand-Foot Skin Reaction and Scrotal Dermatitis in a Patient with Hepatocellular Carcinoma
Dong Il JEONG ; Sang Yeop PARK ; Tae Wook KIM ; Moojung KIM ; Jin Ok BAEK
Korean Journal of Dermatology 2025;63(2):56-60
Regorafenib is an oral multikinase inhibitor used to treat advanced solid tumors, including hepatocellular carcinoma (HCC), gastrointestinal stromal tumors, and colorectal cancer. Adverse dermatological reactions are common after regorafenib treatment. The most frequent cutaneous adverse reaction is hand-foot skin reaction (HFSR). Compared to HFSR, reports on adverse reactions on the scrotum associated with regorafenib are limited. Only a few cases of adverse reactions on the scrotum associated with HFSR have been reported. We present the case of a 55-year-old male patient with a 1-year history of scrotal dermatitis and HFSR, who had been undergoing treatment for HCC.One year after administration of oral regorafenib (160 mg/d), multiple vesicles, pustules, desquamation, and hyperkeratosis developed on both hands and feet, accompanied by scaly erythematous plaques around the scrotum.The lesions improved after two weeks of treatment with topical and systemic steroids. Herein, we report a rare case of scrotal dermatitis associated with regorafenib-induced HFSR.
7.Trends of Syphilis in a Single Tertiary Center:A 24-Year Demographic, Clinical, and Serologic Analysis
Dong Il JEONG ; Sang Yeop PARK ; Tae Wook KIM ; Moojung KIM ; Sanghyun PARK ; Hee Joo KIM ; Jin Ok BAEK
Korean Journal of Dermatology 2025;63(2):29-39
Background:
Syphilis, an infectious and chronic disease primarily transmitted through sexual contact, is caused by the spirochete bacterium Treponema pallidum. Although the introduction of penicillin has significantly reduced its incidence, syphilis continues to have a substantial impact on public health.
Objective:
The purpose of this study was to investigate trends in syphilis and to analyze its epidemiologic, clinical, and serologic characteristics.
Methods:
We retrospectively reviewed the medical records of 330 patients who tested positive for the Venereal Disease Research Laboratory (VDRL) test, including 192 patients who received a diagnosis of syphilis and who visited the Dermatology Department of Gachon University Gil Medical Center between 2000 and 2023. Statistical analyses were performed to evaluate trends in syphilis incidence and related variable factors, such as sex, age, and serological results.
Results:
The average age of the 192 syphilis patients was 34.18±15.81 years, with a male-to-female ratio of 1:1.2. The most prevalent age group was 20∼29 years, comprising 71 patients (37.0%). Over time, the incidence of syphilis demonstrated a decreasing trend (p<0.001). A total of 105 patients (54.7%) were diagnosed with symptomatic syphilis, with a male-to-female ratio of 1.5:1. The proportion of symptomatic syphilis patients tended to decrease with increasing age (p<0.05). Maculopapular syphilis was the most frequently observed presentation in secondary syphilis (36.2%). The proportion of symptomatic syphilis patients significantly increased with higher VDRL titers (p<0.001).
Conclusion
The incidence of syphilis has shown a consistent decline over the past two decades. However, the relatively higher prevalence among younger age groups indicates the need for continued public health efforts.
8.Regorafenib-Induced Hand-Foot Skin Reaction and Scrotal Dermatitis in a Patient with Hepatocellular Carcinoma
Dong Il JEONG ; Sang Yeop PARK ; Tae Wook KIM ; Moojung KIM ; Jin Ok BAEK
Korean Journal of Dermatology 2025;63(2):56-60
Regorafenib is an oral multikinase inhibitor used to treat advanced solid tumors, including hepatocellular carcinoma (HCC), gastrointestinal stromal tumors, and colorectal cancer. Adverse dermatological reactions are common after regorafenib treatment. The most frequent cutaneous adverse reaction is hand-foot skin reaction (HFSR). Compared to HFSR, reports on adverse reactions on the scrotum associated with regorafenib are limited. Only a few cases of adverse reactions on the scrotum associated with HFSR have been reported. We present the case of a 55-year-old male patient with a 1-year history of scrotal dermatitis and HFSR, who had been undergoing treatment for HCC.One year after administration of oral regorafenib (160 mg/d), multiple vesicles, pustules, desquamation, and hyperkeratosis developed on both hands and feet, accompanied by scaly erythematous plaques around the scrotum.The lesions improved after two weeks of treatment with topical and systemic steroids. Herein, we report a rare case of scrotal dermatitis associated with regorafenib-induced HFSR.
9.Risk Factors for the Mortality of Patients With Coronavirus Disease 2019Requiring Extracorporeal Membrane Oxygenation in a Non-Centralized Setting: A Nationwide Study
Tae Wan KIM ; Won-Young KIM ; Sunghoon PARK ; Su Hwan LEE ; Onyu PARK ; Taehwa KIM ; Hye Ju YEO ; Jin Ho JANG ; Woo Hyun CHO ; Jin-Won HUH ; Sang-Min LEE ; Chi Ryang CHUNG ; Jongmin LEE ; Jung Soo KIM ; Sung Yoon LIM ; Ae-Rin BAEK ; Jung-Wan YOO ; Ho Cheol KIM ; Eun Young CHOI ; Chul PARK ; Tae-Ok KIM ; Do Sik MOON ; Song-I LEE ; Jae Young MOON ; Sun Jung KWON ; Gil Myeong SEONG ; Won Jai JUNG ; Moon Seong BAEK ;
Journal of Korean Medical Science 2024;39(8):e75-
Background:
Limited data are available on the mortality rates of patients receiving extracorporeal membrane oxygenation (ECMO) support for coronavirus disease 2019 (COVID-19). We aimed to analyze the relationship between COVID-19 and clinical outcomes for patients receiving ECMO.
Methods:
We retrospectively investigated patients with COVID-19 pneumonia requiring ECMO in 19 hospitals across Korea from January 1, 2020 to August 31, 2021. The primary outcome was the 90-day mortality after ECMO initiation. We performed multivariate analysis using a logistic regression model to estimate the odds ratio (OR) of 90-day mortality. Survival differences were analyzed using the Kaplan–Meier (KM) method.
Results:
Of 127 patients with COVID-19 pneumonia who received ECMO, 70 patients (55.1%) died within 90 days of ECMO initiation. The median age was 64 years, and 63% of patients were male. The incidence of ECMO was increased with age but was decreased after 70 years of age. However, the survival rate was decreased linearly with age. In multivariate analysis, age (OR, 1.048; 95% confidence interval [CI], 1.010–1.089; P = 0.014) and receipt of continuous renal replacement therapy (CRRT) (OR, 3.069; 95% CI, 1.312–7.180; P = 0.010) were significantly associated with an increased risk of 90-day mortality. KM curves showed significant differences in survival between groups according to age (65 years) (log-rank P = 0.021) and receipt of CRRT (log-rank P = 0.004).
Conclusion
Older age and receipt of CRRT were associated with higher mortality rates among patients with COVID-19 who received ECMO.
10.A Standardized Pathology Report for Gastric Cancer: 2nd Edition
Young Soo PARK ; Myeong-Cherl KOOK ; Baek-hui KIM ; Hye Seung LEE ; Dong-Wook KANG ; Mi-Jin GU ; Ok Ran SHIN ; Younghee CHOI ; Wonae LEE ; Hyunki KIM ; In Hye SONG ; Kyoung-Mee KIM ; Hee Sung KIM ; Guhyun KANG ; Do Youn PARK ; So-Young JIN ; Joon Mee KIM ; Yoon Jung CHOI ; Hee Kyung CHANG ; Soomin AHN ; Mee Soo CHANG ; Song-Hee HAN ; Yoonjin KWAK ; An Na SEO ; Sung Hak LEE ; Mee-Yon CHO ;
Journal of Gastric Cancer 2023;23(1):107-145
The first edition of ‘A Standardized Pathology Report for Gastric Cancer’ was initiated by the Gastrointestinal Pathology Study Group of the Korean Society of Pathologists and published 17 years ago. Since then, significant advances have been made in the pathologic diagnosis, molecular genetics, and management of gastric cancer (GC). To reflect those changes, a committee for publishing a second edition of the report was formed within the Gastrointestinal Pathology Study Group of the Korean Society of Pathologists. This second edition consists of two parts: standard data elements and conditional data elements.The standard data elements contain the basic pathologic findings and items necessary to predict the prognosis of GC patients, and they are adequate for routine surgical pathology service. Other diagnostic and prognostic factors relevant to adjuvant therapy, including molecular biomarkers, are classified as conditional data elements to allow each pathologist to selectively choose items appropriate to the environment in their institution. We trust that the standardized pathology report will be helpful for GC diagnosis and facilitate large-scale multidisciplinary collaborative studies.

Result Analysis
Print
Save
E-mail